Reportlinker.com announces that a new market research report is available in its catalogue.
Reportlinker Adds Autoimmune Market Forecast to 2014
Executive Summary:
The autoimmune market is proving that the era of the blockbuster is not dead.
Of 14 brands already at or expected to reach blockbuster status, half generate at least $3 billion annually. Nine mid-level products will generate $400 million, at minimum, by 2014. For autoimmune drugs, reaching blockbuster-level success is an expectation as much as a goal.
Whether you're exploring your options or need to increase your presence in the market, autoimmune compounds provide lucrative opportunities -- don't miss out!
From sales projections to clinical trial data to analysts' insights, Autoimmune Market Forecast to 2014 tells you everything you need to know. Unlike other market forecast reports out there, ours covers all of the major indications - rheumatoid arthritis, ulcerative colitis, Crohn's disease, multiple sclerosis, psoriasis and lupus - profiling 40+ drugs and nine leading autoimmune product manufacturers.
Delve into the data to:
- Learn how brands and drug classes have fared: where they've succeeded - and failed
- Show solid, objective evidence for your decision-making
- Keep track of the competition
- Get the latest on clinical trials
- Uncover potential business development opportunities
If your company is looking to build or vitalize presence in the competitive autoimmune market, you’ll need a tool to give you unshakeable confidence in your decision-making. Autoimmune Market Forecast to 2014 is your all-in-one, comprehensive resource for the most current data available on autoimmune products, drug classes and manufacturers. Expert analysis will help you identify and capitalize on opportunities to chart a clear, profitable course through the market space.
Other reports cover one or two autoimmune indications or only the top drugs at the top companies. Ours covers products for six major conditions psoriasis, lupus, rheumatoid arthritis, Crohn’s disease, ulcerative colitis and multiple sclerosis at different stages of development. Our data analyses are integrated so you understand the contexts and implications that impact the whole market.
Within the report, you’ll find:
- indication history, epidemiology and treatment options
- the brands and drug classes poised to dominate the market
- and those vulnerable
- clinical trial information
- novel therapies -and their status toward market
- autoimmune company strengths, weaknesses, threats and opportunities, how does your company rank among others in this market?
We’ve done the hard work of sifting through and vetting the most relevant data so you don’t have to. Go ahead and be bold, knowing that you’re making smart choices. Use this report today for an immediate impact!
Report Covers:
Product Breakdown:
- 43 Profiled Drugs
- 23 Biologics
- 20 Small Molecules
- 6 Indications
Brand Profile Components:
- Product history
- Competitive and strategic positioning
- Market growth opportunities
- Sales projection charts
- Materiality charts
- Approval histories
- Market exclusivity and patent information (for approved drugs)
- Clinical trial data tables
Company Profile Components:
- Autoimmune market ranking
- Strengths analysis
- Growth areas analysis
- Key products breakdown
Companies Mentioned:
The report analyzes autoimmune portfolios at nine companies that are successful in the autoimmune market. Each company profile examines strategies and identifies strengths and weaknesses.
- Abbott
- Roche
- Centacor (Johnson & Johnson)
- Biogen Idec
- Amgen
- Pfizer
- Schering-Plough (Merck)